1. PAYMENTS AND ROYALTY RATES February 2008 Christi Mitchell, IP Director, Highbury Ltd

2. christi@highburyltd.com2 Christi Mitchell IP Director Human Genetics, Molecular Biology, Marketing and Business Degrees Past President Licensing Executive Society (LES) Britain &Ireland; current Board Director International Chairman, Life Sciences LESI International licensing experience over 25 years International Biotechnology and Healthcare start up and university spin-out company experience Venture Capital experience

3. christi@highburyltd.com3 VALUATION KNOWLEDGE BASED INDUSTRY – CENTRAL TO THE UK ECONOMY –Innovative ideas leading to IP rights and wealth creation: Improved products New brands Creative expressions This process is being increased by the erosion of Global trade barriers

4. christi@highburyltd.com4 Outline. Valuing technology Some valuation methods Key financial terms – royalties

5. christi@highburyltd.com5 Market due diligence Establishing the market potential –potential for viable revenue streams, –cost of independent development –costs of commercialization –impact of previous attempts to commercialize Market sector review including macro factors and market trends –consumer awareness –government constraints

6. christi@highburyltd.com6 Build Financial Model Forecast market size and growth Forecast sales – value & volume Forecast market share (competitor due diligence) Review price structures across all territories Review take to market costs, including: –sales & marketing –IP implementation –Further R&D –Regulatory requirements & hurdles Review distribution chain – risks & costs

7. christi@highburyltd.com7 Other Due Diligence Due Diligence leads to Financial Data –IP due diligence –Product due diligence Forecasts, markets, timeframes, need, take to market route –Partnering costs (legal, other support, time factors, deal implementation) –Corporate due diligence Stability, margins, ethics, reputation

8. christi@highburyltd.com8 Project Process Overview Diagram indicates how Highbury adds value to, and manages the technology/Intellectual Asset commercialisation lifecycle; from idea through to deal implementation.

9. christi@highburyltd.com9 Financial assessment valuation of products / technologies simple financial models risk assessment financial impact of different deal structures royalties

10. christi@highburyltd.com10 Some valuation methods REMEMBER: Agreement on IP valuation is the most difficult hurdle in the negotiation. –Seller focuses on reward –Buyer focuses on the risk Generally made up of lump sum plus royalty ( lump sum/milestone payment scheduling varies across the world)

11. christi@highburyltd.com11 Valuation Insecurity Value depends on 1.Ability of licensee to successfully implement it as a process or product 2.Dependant on a specific market that may be seen differently by the 2 parties 3.The ability to prevent infringement 4.Ability to access licensors know how

12. christi@highburyltd.com12 Simple financial models Valuation methods are based on: Cost – for early technology Potential income – when application is evident Market data – when the technology is developed

13. christi@highburyltd.com13 Cash Flow Analysis what will the investment cost? how much cash will it generate each year? To calculate Cash Flow: –Define the value of the investment –Calculate the size of the benefits –Determine the timing of the benefits –Quantify the uncertainty of the benefits –Do the benefits justify the investment ?? Remember – cash flow is not profit

14. christi@highburyltd.com14 Risk Adjusted Discount Rate This is an adjustment for the time value of money and the inherent risk Calculated risk : –Cost Of Capital + a fudge factor = The Hurdle rate – used to discount future cash flows back to today. The result of summing the Discounted current and future cash flows = The Net Present Value (NPV) +ve NPV = likely good investment (it adds value to the company)

15. christi@highburyltd.com15 Risk assessment/sensitivity analysis Methods to assess risk: Add risk factor to discount rate or create ‘hurdle’ rate e.g.20% Determine sensitivity of model to various unknowns by calculating different scenarios, e.g. - lower price or market share - development costs are higher - development takes longer - cost of goods are higher than forecast

16. christi@highburyltd.com16 Other valuation methods DCF (Discounted Cash Flow) – Problem,“The future cash flows of raw technology are uncertain” Monte Carlo – A mean estimate of cash flows, and statistically modelled range of expected cash flows. –Produces an unbiased distribution of present values where the mean can be taken. (objective method) Capital Asset Pricing Model (CAPM) –Adjust the “Hurdle Rate” based on the amount of “systemic risk” = Risk Adjusted Discount Rate (RADR) –This allows degrees of risk to be incorporated

17. christi@highburyltd.com17 Key financial terms Equity investment –control Upfront payments –commitment Milestone payments –risk sharing Other payments –e.g. manufacturing facility, research, patent or clinical costs Royalties –profit sharing

18. christi@highburyltd.com18 Most important factors affecting Royalty Rates oStrength of IP oMarket sector (expected norms) oDegree of exclusivity (field of use restrictions) oLicensor/Licensee characteristics oEconomic factors oPhase of development oDuration and scope of license oCommitment to ongoing research oNegotiating skills oDegree of need

19. christi@highburyltd.com19 Generic IA Biotech Value Drivers Value Drivers –Market Reached peak? Growth rate Market share –Cost Operating development –Time Patent life Proof of concept –Option Strategic operating Risk Drivers –Internal risk Strategic fit or dilution –Substance risk Safety Efficacy availability –Competitor risk In class Out of class –Commercial risk Image Economics

20. christi@highburyltd.com20 Royalty rates: Industry Norms What are they? What don’t they tell us? Are they useful? How can we use them?

21. christi@highburyltd.com21 Royalty rates: Industry Norms Franklin Pierce Law Centre IndustryRoyalty Norm Chemical1-5% Computers3-5% Consumer Products2% Electronics<1-5% Pharmaceuticals4-15%

22. christi@highburyltd.com22 Industry Norms What don’t they tell us? the range of royalty values the stage of development to what the royalty rate relates what other financial components exist –Down payments –Milestone payments –Equity etc. any other aspects of the deal –Exclusivity –Timing of payments etc.

23. christi@highburyltd.com23 Financial negotiation market estimates –establish a baseline –share market data –agree top line figures openly discuss key assumptions identify corporate drivers –fixed hurdles - NPV / IRR –turnover of £ X m

24. christi@highburyltd.com24 Risk verses Reward Licensee prefers royalty –Allows them to limit the consequence of uncertainty Licensor prefers (dp) downpayment –Quicker rate of return –Will not share licensees implementation risk –Avoids royalty mismanagement by licensee –Requires less enforcement/monitoring than royalty –Dp raises negotiation cost (requires greater due diligence to get the price right)

25. christi@highburyltd.com25 Timing early payments –carry high risk to the licensee –have high impact on NPV late stage payments –are paid on specific target achievements –carry lower impact on NPV

26. christi@highburyltd.com26 Agreement provisions clear payment terms –timing and delivery –currency exchange provisions –late payment –CIF/FOB manufacturing / QC royalty audit provisions

27. christi@highburyltd.com27 Conclusions Relating risk to reward is difficult There are many valuation methods IP values are not static Industry norms only tell part of the story Patents lapse, value may not hold into perpetuity Use a mix of valuation methods

28. christi@highburyltd.com28 Contact Christi Mitchell: –Intellectual Property Director Direct Tel: +44(0)1462436894 christi@highburyltd.com Elizabeth McNabb: –International Business Development Director Direct Tel: +44(0)20835556989 elizabeth@highburyltd.com Anne Wight: –Business Development Director Highbury Pacific Direct Tel: +64(0) 21432424 anne@highburyltd.com